Invesco BLDRS Europe Select ADR Index Fund

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.

    By Mike Benson
  • uploads///business _
    Miscellaneous

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.

    By Mike Benson
  • uploads///doctor _
    Company & Industry Overviews

    EC Approves GSK’s Nucala for Children with Severe Asthma

    On August 30, GlaxoSmithKline (GSK) announced that the EC approved Nucala for pediatric patients with severe refractory eosinophilic asthma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Sandoz in Q2 2018

    Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    Novartis’s SOLAR-1 Trial Met Primary Endpoint

    Novartis (NVS) announced on August 23 that its SOLAR-1 trial evaluating alpelisib combined with fulvestrant has met its primary endpoint.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.

    By Mike Benson
  • uploads///Chart  NVS
    Company & Industry Overviews

    Assessing the Performance of Novartis Stock in 1Q18

    Novartis stock has fallen ~7.0% in 1Q18, and it’s fallen 4.5% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Alcon Performed in 4Q17

    Alcon reported 8% growth in revenues to ~$1.6 billion during 4Q17 as compared to ~$1.4 billion in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Other Products Portfolio Performed in 4Q17

    AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Generics and Consumer Healthcare Portfolios in 4Q17

    Sanofi’s consumer healthcare portfolio reported revenues of 1.2 billion euros in 4Q17, reflecting 51.8% growth in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///alx
    Company & Industry Overviews

    How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy

    Sanofi (SNY) is consistently investing in and focusing on its R&D (research and development) strategy. The company has a number of key technology platforms driving its multitargeting strategy in R&D.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Earnings: Segment-Wise Revenues

    Novartis (NVS) reported revenues of ~$12.9 billion in 4Q17, representing 5.0% growth in revenues compared to ~$12.3 billion in 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Shingrix Could Be a Long-Term Growth Driver for GlaxoSmithKline

    On October 20, 2017, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) Zoster vaccine recombinant and adjuvanted vaccine, Shingrix.

    By Margaret Patrick
  • uploads///q_sales
    Company & Industry Overviews

    Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’

    On January 9, 2018, Mizuho Securities upgraded Teva Pharmaceutical Industries (TEVA) from a “neutral” to a “buy” rating. It came after Teva announced its business restructuring plan.

    By Sarah Collins
  • uploads///Lucentis
    Company & Industry Overviews

    How Is Novartis’s Lucentis Positioned after 1H17?

    In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Respiratory revenues
    Company & Industry Overviews

    How TEVA’s Respiratory Franchise Is Positioned after 1H17

    In 1H17, Teva Pharmaceutical’s (TEVA) respiratory franchise reported revenues of ~$626 million, or ~8% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Chart  SWR
    Company & Industry Overviews

    AstraZeneca’s Segment-Wise Performance in 2Q17

    At constant exchange rates, AstraZeneca reported an 8% decline in its product sales of ~$4.9 billion during 2Q17.

    By Mike Benson
  • uploads///Chart  ERx
    Company & Industry Overviews

    Performance of Sanofi’s Established Products in 2Q17

    Established products Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower sales of Plavix, Lovenox, Allegra, Myslee, Lasix, and a few other drugs were substantially offset by strong performance by Renagel, Renvela, Aprovel, Synvisc, […]

    By Mike Benson
  • uploads///Chart  HIV
    Earnings Report

    GlaxoSmithKline’s 2Q17 Earnings: HIV Business

    GSK’s HIV Products franchise reported growth of 29.0% to ~1.1 billion pounds in 2Q17 compared to 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Novartis’s Financial Guidance and Priorities for 2017

    Novartis expects to absorb the impact of generic competition and expects its 2017 sales to be in line with its 2016 revenue at a constant exchange rate.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.